LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

Kodu・Aktsiate loetelu・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Suletud

SektorTervishoid

28.35 2.2

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

27.89

Max

28.83

Põhinäitajad
By Trading Economics
Sissetulek	-28M 22M
Müük	4.3M 244M
P/E Sektori keskmine	10.28 57.833
Aktsiakasum	1.08
Kasumimarginaal	9.224
Töötajad	293
EBITDA	-22M 52M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+48.06% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. mai 2026

Turustatistika
By TradingEconomics
Turukapital	64M 1.6B
Eelmine avamishind	26.15
Eelmine sulgemishind	28.35

Uudiste sentiment

By Acuity

75%

25%

324 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

29.8 / N/A Toetus ja vastupanu

Harmony Biosciences Holdings Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. märts 2026, 22:42 UTC

Tulu

Prudential PLC 2025 Adjusted Operating Profit Rises

17. märts 2026, 21:40 UTC

Tulu

Alimentation Couche-Tard Records Higher Profit, Revenue in 3Q

17. märts 2026, 23:56 UTC

Market Talk

BHP's Next CEO Likely to Build On Existing Strategic Direction -- Market Talk

17. märts 2026, 23:46 UTC

Market Talk

Nikkei May Rise After Recent Selloffs -- Market Talk

17. märts 2026, 23:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. märts 2026, 23:42 UTC

Market Talk

RBA's Return to Policy Tightening Will Work -- Market Talk

17. märts 2026, 23:38 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustments Before FOMC Decision -- Market Talk

17. märts 2026, 23:24 UTC

Market Talk

Global Energy Roundup: Market Talk

17. märts 2026, 23:24 UTC

Market Talk

New Woodside CEO Seen as Low-Risk Appointment -- Market Talk

17. märts 2026, 22:22 UTC

Market Talk

BHP Hands Reins to Growth-Focused Executive -- Market Talk

17. märts 2026, 22:20 UTC

Tulu

Prudential PLC 2025 New Business Profit $2.78B Vs. $2.46B >2378.HK

17. märts 2026, 22:20 UTC

Tulu

Prudential PLC 2025 Adj Operating Profit $3.31B Vs. $3.13B >2378.HK

17. märts 2026, 22:07 UTC

Tulu

Nvidia Says It Is Restarting Production of AI Chips for Sale in China -- WSJ

17. märts 2026, 22:05 UTC

Tulu

ZTO Express (Cayman): Frank Zhen Wei to Resign From Board

17. märts 2026, 22:04 UTC

Tulu

ZTO Express (Cayman): Board Approves Repurchase of Up to $1.5B of Shares Over Next 24 Months >ZTO

17. märts 2026, 22:03 UTC

Tulu

ZTO Express (Cayman) Raises Semiannual Dividend to 39c Vs. 30c >ZTO

17. märts 2026, 22:01 UTC

Tulu

ZTO Express (Cayman) 4Q Adj EPS 47c >ZTO

17. märts 2026, 22:01 UTC

Tulu

ZTO Express (Cayman) 4Q Rev $2.08B >ZTO

17. märts 2026, 22:01 UTC

Tulu

ZTO Express (Cayman) 4Q EPS 47c >ZTO

17. märts 2026, 21:26 UTC

Tulu

Oklo Stock Wavers After Earnings, but the Nuclear Start-Up Has Good News -- Barrons.com

17. märts 2026, 21:09 UTC

Tulu

Couche-Tard: 12 Company-Operated Stores Acquired During 3Q

17. märts 2026, 21:08 UTC

Tulu

Couche-Tard 3Q Consolidated Same-Store Merchandise Revenue Up 2% >ATD.T

17. märts 2026, 21:08 UTC

Tulu

Couche-Tard 3Q Adj EPS 81c >ATD.T

17. märts 2026, 21:07 UTC

Tulu

Couche-Tard 3Q EPS 82c >ATD.T

17. märts 2026, 21:06 UTC

Tulu

Couche-Tard 3Q Rev $21.8B >ATD.T

17. märts 2026, 21:05 UTC

Tulu

Couche-Tard 3Q Adj EPS 81c >ATD.T

17. märts 2026, 21:05 UTC

Tulu

Couche-Tard 3Q Rev $21.8B >ATD.T

17. märts 2026, 21:05 UTC

Tulu

Couche-Tard 3Q EPS 82c >ATD.T

17. märts 2026, 21:05 UTC

Tulu

Couche-Tard 3Q Net $757.2M >ATD.T

17. märts 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Energy & Utilities Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Harmony Biosciences Holdings Inc Prognoos

Hinnasiht

By TipRanks

48.06% tõus

12 kuu keskmine prognoos

Keskmine 41.25 USD 48.06%

Kõrge 62 USD

Madal 25 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Harmony Biosciences Holdings Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Harmony Biosciences Holdings Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

29.8 / N/AToetus ja vastupanu

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

324 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.